On March 23, 2026 BostonGene, developer of the leading AI foundation model for tumor and immune biology, reported an oral presentation at the United States and Canadian Academy of Pathology (USCAP) 115th Annual Meeting. The session highlights new clinical data generated in collaboration with leading academic investigators, including Weill Cornell Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event, held from March 21-26 at the Henry B. González Convention Center in San Antonio, TX, is the world’s premier gathering for pathology professionals serving as a critical global platform for clinicians and researchers to exchange cutting-edge research and educational insights across pathology subspecialties, with a particular focus on the integration of AI and molecular advancements into clinical practice.

The study, which demonstrates a multimodal AI framework trained on approximately 20,000 tumors, will be presented by Juan Miguel Mosquera, MD, MSc. Dr Mosquera is a Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine and Director of Research Pathology at the Englander Institute for Precision Medicine, and is widely recognized for his contributions to cancer genomics and biomarker development with more than 130 peer-reviewed publications.

The research integrated whole exome and transcriptomic data to address cancers of unknown primary (CUP). In real-world cases, the framework accurately identified tumor origin while uncovering actionable therapeutic targets in more than 65% of patients, including FDA-approved options.

The results reflect a broader shift from traditional tumor classification toward AI-driven disease modeling, enabling deeper biological understanding, more precise patient stratification, and improved treatment selection.

Details of the oral presentation are below:

Abstract: 942
Title: Cancer of Unknown Primary (CUP): Beyond the Identification of the Tumor of Origin by an Integrative Whole Exome (WES) and Transcriptome Sequencing (RNAseq) Approach
Date & Time: Tuesday, March 24 | 8:30 AM – 8:45 AM
Location: Room 303B
Presenter: Juan Miguel Mosquera, MD, MSc, Weill Cornell Medicine

Research done in collaboration with Weill Cornell Medicine

(Press release, BostonGene, MAR 23, 2026, View Source [SID1234663846])